Phenom Expands Applied AI Leadership: Enterprise Talent Optimization & Work Redesign, Frontline Workforce Lifecycle & Shift Scheduling, and Unified Orchestration Engine
7.11.2025 11:00:00 CET | Business Wire | Press Release
Phenom, the leader in applied AI that helps organisations hire faster, develop better and retain longer, announced three new innovations at IAMPHENOM Europe that enhance how companies connect business strategy to talent execution: Enterprise Talent Optimization & Work Redesign, Frontline Workforce Lifecycle & Shift Scheduling, and Unified Orchestration Engine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107190121/en/
Phenom announced three new innovations at IAMPHENOM Europe that enhance how companies connect business strategy to talent execution: Enterprise Talent Optimization & Work Redesign, Frontline Workforce Lifecycle & Shift Scheduling, and Unified Orchestration Engine. By expanding Phenom’s AI and automation, companies are empowered to rethink how work is designed, talent is mobilised and operations are orchestrated across the full talent lifecycle.
By expanding Phenom’s AI and automation, companies are empowered to rethink how work is designed, talent is mobilised and operations are orchestrated across the full talent lifecycle. Built on Phenom X+ Ontologies, these products adapt to industry nuances, regulatory requirements, and the distinct needs of knowledge workers and frontline teams.
Traditional talent approaches have created persistent gaps: Enterprises have workforce data that cannot be turned into coordinated action; strategic priorities do not automatically translate into hiring plans; promising talent sits undiscovered in organisational silos; and policies designed for compliance create operational gridlock. Additionally, frontline workers continue to lack the same depth of resources and tools available to their corporate colleagues. Closing these gaps requires AI and agents that move beyond analysis to actively drive execution — connecting strategy, operations and people in real time.
Enterprise Talent Optimization & Work Redesign: Aligning Employee Engagement to Business Strategy
Most organisations are not leveraging skills to drive talent planning, reduce hiring costs and expedite productivity. This is due to complexities in collecting validated skills data from employees and understanding how skills specifically relate to the completion of work and the impact on company goals.
Phenom Enterprise Talent Optimization & Work Redesign connects business strategy directly to talent action. Managers can launch any strategic initiative, from a department project to opening a new store or expanding into new markets, and AI instantly maps the workforce implications: identifying required skills, affected roles, and tasks that can be automated or AI-augmented.
With these capabilities, enterprises can leverage:
- AI-driven task intelligence to analyse each role at the task level, revealing what can be automated or enhanced with AIwe
- Conversational AI agents to gather talent insights from employees and managers as part of natural career discussions, enriching workforce data without administrative burden
- Career coach agents to connect employee development to company objectives, building growth plans tied directly to business outcomes
Each program is measurable, connecting talent actions to business progress. Powered by task ontologies, Enterprise Talent Optimization & Work Redesign sets the foundation for dynamic workforce and succession planning and skill governance, while embedded AI agents eliminate manual data maintenance.
Frontline Workforce Lifecycle & Shift Scheduling: Coordinating Shifts, Managing Policies & Personalising Interactions
Following global success with hiring automation and vertical-specific onboarding, Phenom is enhancing the frontline experience to encompass the entire workforce lifecycle, including shift scheduling, internal mobility, referrals, communication and alumni engagement.
This allows organisations to move beyond traditional app-based experiences into an agentic, conversational model. AI agents help frontline employees and managers coordinate scheduling and career development, while ensuring it is personalised at every step.
Enterprises can leverage AI to handle:
- Shift scheduling with built-in European Union and country-specific Working Time Directive compliance
- Dynamic shift optimisation that considers employee preferences, skills and availability in real time
- Internal mobility and referrals integration that enable employees to swap or recommend shifts internally for a broader picture of career growth
- Alumni communities that empower managers to reach former employees for part-time or seasonal roles, strengthening employer connections and accelerating rehiring
By combining these three new technology innovations with lifecycle intelligence and compliance automation, Phenom creates a more connected, compliant and human experience for Europe’s essential workforce.
Unified Orchestration Engine: Catching Automation Exceptions & Keeping HRIT in Control
Traditional automation tools are rigid and break when exceptions occur. Phenom Unified Orchestration Engine introduces adaptive intelligence that handles exceptions in real time. Combining decision engines with simulations guided by agent operating policies and human-in-the-loop governance, it orchestrates workflows across the talent ecosystem while keeping humans in control.
By allowing AI agents to participate directly in workflows, they can identify bottlenecks, create alternative pathways when rules don't fit, and ensure every action is policy-compliant and explainable. For example, they can:
- Automatically reschedule interviews when a manager doesn't show up
- Escalate to recruiters when resume parsing fails
- Enforce region-specific compliance rules for shift scheduling
- Simulate policy changes and visualise downstream impact before rollout
Companies control which tasks agents can automate and which require human judgment, with built-in compliance guardrails. Unified Orchestration Engine makes policy definition intuitive, turning rigid automation into transparent, adaptive orchestration.
“Traditional HR strategies force employees and managers into admin tasks that don’t reflect how work actually gets done,” said Mahe Bayireddi, CEO and co-founder of Phenom. “What we do at Phenom is different. We don’t just build AI, we apply it to the real world. That means intelligence that connects strategy to talent decisions, automation that adapts to complexity and experiences that engage every worker. With applied AI that optimises and adapts, enterprises redesign work from administrative overhead to meaningful impact.”
With Phenom, candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become wildly productive, talent marketers engage with extreme efficiency, talent leaders optimise hiring and onboarding processes, managers build stronger-performing teams, HR aligns employee development with company goals, and HRIT easily integrates existing HR tech to create a holistic infrastructure.
Discover how Phenom Applied AI empowers organisations to hire faster, develop better and retain longer here.
About Phenom
Phenom is an applied AI company that helps organizations hire faster, develop better and retain longer. By uniquely combining proprietary industry-specific AI, agentic AI, automation and personalized experiences, its Intelligent Talent Experience platform helps companies fundamentally reshape their HR processes and strategies for scalable and sustainable transformation. Driven by a purpose to help a billion people find the right work, Phenom takes a holistic approach that unifies the entire talent journey, augmenting human capabilities and creating a symbiotic relationship between technology and talent.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (6 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), 11 Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in Generative AI for Business Impact,’ Business Intelligence Group’s Artificial Intelligence Excellence Awards (3 consecutive years), The Cloud Awards 2025/2024, The A.I. Awards 2024, and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, X, Facebook, YouTube, Instagram and TikTok.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251107190121/en/
Contacts
Jennifer Lyons
Sr. Director, Global Communications
Phenom
267-379-5066
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom